Merck Announces That The Phase 3 KEYNOTE-361 Trial Evaluating KEYTRUDA As Monotherapy And In Combination With Chemotherapy In Patients With Advanced Or Metastatic Urothelial Carcinoma
Benzinga Newsdesk